Nuvalent, Inc. (NUVL)
100.55
+0.65
(+0.65%)
USD |
NASDAQ |
May 19, 11:34
Nuvalent Research and Development Expense (Quarterly) : 83.61M for March 31, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Cogent Biosciences, Inc. | 74.21M |
| Neurocrine Biosciences, Inc. | 296.20M |
| BioMarin Pharmaceutical, Inc. | 178.80M |
| Kodiak Sciences, Inc. | 48.55M |
| Olema Pharmaceuticals, Inc. | 49.23M |